
|Videos|May 26, 2022
Choosing a Combination Therapy for Renal Cell Carcinoma Before and After CLEAR Data
Author(s)Brian Shimkus, MD, Tom Powles, MBBS, MRCP, MD
Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
4
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
5


































































